CCChristopher V. Chien

Christopher V. Chien

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher V. Chien has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trajectories of Dyspnea After Heart Failure Hospitalization: A Prospective Longitudinal Cohort Study

    by Quin E. Denfeld, Shirin O. Hiatt, S. Albert Camacho, Christopher V. Chien, Nathan F. Dieckmann, Christopher S. Lee

  • Open Access

    Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF

    by Akshay S. Desai, Michael R. Zile, Anique Ducharme, Mandeep R. Mehra, Alan S. Maisel, Samuel F. Sears, Maria Rosa Costanzo, Frank W. Smart, Christopher V. Chien, Orvar Jonsson, et al.

    BACKGROUND: While clinical benefits of guideline-directed medical therapy in patients with heart failure (HF) are well established, acute hemodynamic changes after initiation of these agents are not well described. Wireless pulmonary artery pressure (PAP) monitoring using implantable sensors is ideally suited to determine changes in pressure following medication titration. METHODS: We compared PAP from 7 days pre-initiation to the 7-day period following 30 days of newly initiated treatment with core HF therapies: angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose co-transporter-2 inhibitors, and β-blockers in patients implanted with a PAP sensor (CardioMEMS, Abbott) as part of the GUIDE-HF study (Hemodynamic-Guided Management of HF). Patients with changes in loop diuretics or other core HF therapies during the 30-day interval were excluded from the analysis. RESULTS: Of 2358 patients in the study, 50 patients had new angiotensin receptor-neprilysin inhibitor initiation, 97 patients had new sodium-glucose co-transporter-2 inhibitor initiation, 112 patients had new mineralocorticoid receptor antagonist initiation, and 33 had new β-blocker initiation at least 30 days post-implant, continued to take the medication for at least 30 days, and were included in this analysis. Following angiotensin receptor-neprilysin inhibitor or mineralocorticoid receptor antagonist initiation, diastolic PAP decreased by −1.56 (95% CI, −3.54 to −0.40) and −1.15 (95% CI, −1.82 to −0.47) mm Hg, respectively, in the absence of changes in loop diuretics or other core HF therapies. By contrast, there was no detectable change in PAP following the new initiation of the sodium-glucose co-transporter-2 inhibitor. A trend to higher PAP was observed after β-blocker initiation though differences were not significant. CONCLUSIONS: These results may inform the selection of pharmacological therapy to manage elevated filling pressures during hemodynamic-guided therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387813.


  • Remote Measurement of Volume Status in Heart Failure

    by Nayan Arora, Conrad J. Macon, Christopher Chien

    Heart failure admissions are driven by elevated cardiac filling pressures culminating in symptoms of congestion and result in a significant burden to both patients and society. Traditional strategies of monitoring changes in weight and symptoms to trigger adjustments in therapy, even when combined with telemedicine services, have failed to improve outcomes. Implantable hemodynamic monitors allow clinicians to obtain meaningful, objective data, with an opportunity for early intervention to improve outcomes. Patients with concomitant kidney disease represent a particularly vulnerable population with higher rates of hospitalization compared with patients with heart failure and normal kidney function. Several studies have demonstrated a reduction in hospitalization rates with the use of ambulatory hemodynamic monitors. In the following review, we discuss the existing literature, including studies in patients with kidney disease, and highlight future innovations in the field.

  • Medicare Coverage and Patient Out-of-Pocket Costs for Mavacamten

    by Kannu Bansal, Christopher V. Chien, Ahmad Masri, Ralph J. Riello, Tariq Ahmad, Nihar R. Desai, Sourbha S. Dani

  • Open Access

    Left Ventricular Assist Device Decommissioning: Challenging the Standard of Care

    by Grayson C. Eubanks, Christopher V. Chien, Elizabeth M. Volz, Mirnela Byku

    The number of LVAD implants continues to increase as advanced heart failure becomes more prevalent. Despite good medical therapy, true myocardial reco

  • Open Access

    The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic

    by Michael R Zile, Akshay S Desai, Maria Rosa Costanzo, Anique Ducharme, Alan Maisel, Mandeep R Mehra, Sara Paul, Samuel F Sears, Frank Smart, Christopher Chien, et al.

    During the coronavirus disease 2019 (COVID-19) pandemic, important changes in heart failure (HF) event rates have been widely reported, but few data address potential causes for these changes; several possibilities were examined in the GUIDE-HF study. From 15 March 2018 to 20 December 2019, patients were randomized to haemodynamic-guided management (treatment) vs. control for 12 months, with a primary endpoint of all-cause mortality plus HF events. Pre-COVID-19, the primary endpoint rate was 0.553 vs. 0.682 events/patient-year in the treatment vs. control group [hazard ratio (HR) 0.81, P = 0.049]. Treatment difference was no longer evident during COVID-19 (HR 1.11, P = 0.526), with a 21% decrease in the control group (0.536 events/patient-year) and no change in the treatment group (0.597 events/patient-year). Data reflecting provider-, disease-, and patient-dependent factors that might change the primary endpoint rate during COVID-19 were examined. Subject contact frequency was similar in the treatment vs. control group before and during COVID-19. During COVID-19, the monthly rate of medication changes fell 19.2% in the treatment vs. 10.7% in the control group to levels not different between groups (P = 0.362). COVID-19 was infrequent and not different between groups. Pulmonary artery pressure area under the curve decreased −98 mmHg-days in the treatment group vs. −100 mmHg-days in the controls (P = 0.867). Patient compliance with the study protocol was maintained during COVID-19 in both groups. During COVID-19, the primary event rate decreased in the controls and remained low in the treatment group, resulting in an effacement of group differences that were present pre-COVID-19. These outcomes did not result from changes in provider- or disease-dependent factors; pulmonary artery pressure decreased despite fewer medication changes, suggesting that patient-dependent factors played an important role in these outcomes. Clinical Trials.gov: NCT03387813 Patient-dependent factors played an important role in the outcomes of GUIDE-HF.


  • Patterns and predictors of dyspnoea following left ventricular assist device implantation

    by Kenneth M Faulkner, Corrine Y Jurgens, Quin E Denfeld, Christopher V Chien, Jessica Harman Thompson, Jill M Gelow, Kathleen L Grady, Christopher S Lee

    Dyspnoea is a common symptom of heart failure (HF) that often prompts patients to seek treatment. Implantation of a left ventricular assist device (LVAD) has been associated with reduced dyspnoea but it is unclear if all patients experience similar improvements in dyspnoea over time following LVAD implantation. Our aim was to identify distinct trajectories of dyspnoea symptoms over time following LVAD implantation and predictors of dyspnoea trajectory. We hypothesized that at least two, distinct trajectories of dyspnoea would be observed following LVAD implantation. This was a secondary analysis of data from the Profiling Biobehavioral Responses to Mechanical Support in Advanced Heart Failure study. In the parent study, sociodemographic and clinical data were collected prior to LVAD implantation and at 1, 3, and 6 months following LVAD implantation from a sample (n = 101) of patients with advanced HF. Latent growth mixture modelling was performed to identify distinct trajectories of dyspnoea symptoms. Backwards stepwise logistic regression was used to identify predictors of dyspnoea trajectory. Two, distinct trajectories of dyspnoea symptoms were identified: sustained improvement and unsustained improvement. Participants who experienced sustained improvement (86.7% of sample) demonstrated large, significant improvement in dyspnoea from pre-implantation to 3 months post-implant followed by smaller, non-significant improvement from 3 to 6 months. Participants who experienced unsustained improvement (13.3% of sample) demonstrated initial improvement from pre-implantation to 3 months post-implantation followed by worsening of dyspnoea from 3 to 6 months. Greater depressive symptoms at baseline and living alone were significant predictors of unsustained improvement. Patients experience different patterns of dyspnoea over time following LVAD implantation. Clinicians should inquire about living arrangements and depressive symptoms at each visit to determine risk of unsustained improvement in dyspnoea.


  • Author Response to “Referring Women for Advanced Heart Failure Therapies: Too Little, Too Late”

    by Jared J. Herr, Michael Tong, Benjamin D'SOuza, Farooq Sheikh, Anuradha Lala, Christopher Chien, Ashwin Ravichandran